Search research articles
Contact Us
Filters
Showing results (191-200 of 332) with videos related to
Page
of 34
Sort By:
Hematological Oncology
|
March 8, 2019
Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations
Evgenii Shumilov, Johanna Flach, Raphael Joncourt, et al.
Blood
|
April 28, 2005
CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)
Daniel Helbling, Beatrice U Mueller, Nikolai A Timchenko, et al.
Frontiers in Immunology
|
August 14, 2018
Host-Derived Microvesicles Carrying Bacterial Pore-Forming Toxins Deliver Signals to Macrophages: A Novel Mechanism of Shaping Immune Responses
René Köffel, Heidi Wolfmeier, Yu Larpin, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
Evgenii Shumilov, Paolo Mazzeo, Martin S Zinkernagel, et al.
Blood Advances
|
September 12, 2019
Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome
Anne Angelillo-Scherrer, Behrouz Mansouri Taleghani, Frauke Förger, et al.
Bone Marrow Transplantation
|
April 21, 2022
Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
Sarah Farag, Ulrike Bacher, Barbara Jeker, et al.
Leukemia & Lymphoma
|
April 4, 2013
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07)
Jakob R Passweg, Thomas Pabst, Sabine Blum, et al.
Hematological Oncology
|
September 29, 2016
Y<sup>90</sup> -Ibritumomab tiuxetan (Y<sup>90</sup> -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
Michèle Voegeli, Stephanie Rondeau, Simona Berardi Vilei, et al.
Swiss Medical Weekly
|
January 29, 2025
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature
Ramona Meier-Lienhard, Cosima Suter, Thomas Pabst, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 25, 2004
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin
Daniel Helbling, Beatrice U Mueller, Nikolai A Timchenko, et al.
Page
of 34
Search research articles
Search
Showing results (191-200 of 332) with videos related to
Sort By:
Page
of 34
Hematological Oncology
|
March 8, 2019
Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations
Evgenii Shumilov, Johanna Flach, Raphael Joncourt, et al.
Blood
|
April 28, 2005
CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)
Daniel Helbling, Beatrice U Mueller, Nikolai A Timchenko, et al.
Frontiers in Immunology
|
August 14, 2018
Host-Derived Microvesicles Carrying Bacterial Pore-Forming Toxins Deliver Signals to Macrophages: A Novel Mechanism of Shaping Immune Responses
René Köffel, Heidi Wolfmeier, Yu Larpin, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
Evgenii Shumilov, Paolo Mazzeo, Martin S Zinkernagel, et al.
Blood Advances
|
September 12, 2019
Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome
Anne Angelillo-Scherrer, Behrouz Mansouri Taleghani, Frauke Förger, et al.
Bone Marrow Transplantation
|
April 21, 2022
Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
Sarah Farag, Ulrike Bacher, Barbara Jeker, et al.
Leukemia & Lymphoma
|
April 4, 2013
Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07)
Jakob R Passweg, Thomas Pabst, Sabine Blum, et al.
Hematological Oncology
|
September 29, 2016
Y<sup>90</sup> -Ibritumomab tiuxetan (Y<sup>90</sup> -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
Michèle Voegeli, Stephanie Rondeau, Simona Berardi Vilei, et al.
Swiss Medical Weekly
|
January 29, 2025
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature
Ramona Meier-Lienhard, Cosima Suter, Thomas Pabst, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 25, 2004
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin
Daniel Helbling, Beatrice U Mueller, Nikolai A Timchenko, et al.
Page
of 34